10-Q: Allogene Therapeutics Reports Q2 2025, Shifts Clinical Focus

Allogene Therapeutics reported a reduced net loss in Q2 2025, extended its cash runway into late 2027, and advanced key clinical programs while discontinuing a lymphodepletion agent due to a serious adverse event.

Summary

• Net loss for the three months ended June 30, 2025, was $50.9 million, a decrease from $66.4 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $110.7 million, down from $131.4 million for the same period in 2024.
• Cash, cash equivalents, and investments totaled $302.6 million as of June 30, 2025, with an expected cash runway into the second half of 2027.
• The company approved an approximately 28% reduction in its employee workforce in May 2025, incurring $3.3 million in cash-based severance payments and other benefits.
• The ALPHA3 trial for cema-cel in large B-cell lymphoma (LBCL) will now proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion only, following a Grade 5 adverse event (hepatic failure from disseminated adenovirus infection) in the FC plus ALLO-647 (FCA) arm, which was attributed to ALLO-647.
• Development of ALLO-647 has been terminated across all trials.
• The TRAVERSE trial for ALLO-316 in renal cell carcinoma (RCC) completed enrollment of 20 patients in its Phase 1b expansion cohort, and the company has aligned with the FDA on the design of a registration trial.
• ALLO-316 received Regenerative Medicine Advanced Therapy (RMAT) designation.
• The RESOLUTION trial for ALLO-329 in autoimmune diseases (AID) has initiated Phase 1, and ALLO-329 received three Fast Track Designations (FTD) for systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc).
• Impairment charges of $2.4 million were recognized for the six months ended June 30, 2025, related to a subleased building and equipment due to the workforce reduction.

Sentiment

Score: 4

Explanation: While the company has extended its cash runway and is making progress in some clinical programs (RMAT, Fast Track), the significant net losses, substantial accumulated deficit, workforce reduction, and especially the Grade 5 SAE leading to the discontinuation of a key lymphodepletion agent (ALLO-647) in a pivotal trial, indicate considerable challenges and risks. The future outlook is highly dependent on successful clinical outcomes and further capital raises.

Positives

• Net loss decreased by 23% for Q2 2025 and 16% for H1 2025 compared to the prior year periods, indicating improved operational efficiency or reduced spending.
• Cash, cash equivalents, and investments of $302.6 million as of June 30, 2025, are expected to fund operations into the second half of 2027, providing a longer cash runway.
• ALLO-316 (RCC) received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process.
• Alignment with the FDA on the design of a registration trial for ALLO-316 suggests a clear path forward for this program.
• ALLO-329 (autoimmune diseases) IND cleared and Phase 1 RESOLUTION trial initiated, marking progress into a new therapeutic area.
• ALLO-329 received three Fast Track Designations (SLE, IIM, SSc), potentially accelerating its development and review.
• The ALPHA3 trial for cema-cel in LBCL continues with a revised lymphodepletion regimen, maintaining progress towards a futility analysis in H1 2026.
• Expansion of the CD19 license territory to include the European Union and the United Kingdom, with an option for China and Japan, broadens potential market opportunities.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $1.93 billion as of June 30, 2025.
• A workforce reduction of approximately 28% was implemented in May 2025, indicating ongoing cost-cutting measures and potential operational challenges.
• A Grade 5 serious adverse event (hepatic failure from disseminated adenovirus infection) occurred in the ALPHA3 trial's FCA arm, attributed to ALLO-647, leading to its discontinuation and termination of ALLO-647 development.
• The uncertainty regarding whether the standard FC lymphodepletion regimen alone will achieve sufficient efficacy in the ALPHA3 trial introduces clinical risk.
• The company recognized $2.4 million in impairment charges for long-lived assets in H1 2025, reflecting asset value reductions.
• Reliance on third-party diagnostic (Foresight Diagnostics CLARITY MRD test) for ALPHA3 patient selection introduces external dependencies and risks.

Risks

• The company has incurred net losses since inception and anticipates substantial net losses in the future, requiring significant expenditures for research, development, and manufacturing.
• Substantial additional financing will be needed to develop products and implement operating plans; failure to obtain could delay or halt development and commercialization.
• Product candidates are based on novel technologies, making it difficult to predict development time, cost, and likelihood of regulatory approval.
• The business is highly dependent on the success of lead product candidates (cema-cel, ALLO-316, ALLO-329); failure of any could significantly harm the business.
• Product candidates may cause undesirable side effects (e.g., CRS, neurotoxicity, GvHD, IEC-HS, prolonged cytopenia, aplastic anemia, serious infections) that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• Risks related to serious adverse events (SAEs) in the discontinued FCA arm of the ALPHA3 trial, including the Grade 5 SAE, could lead to regulatory actions, negative perceptions, and potential product liability claims.
• No CAR T therapy has been approved as part of a first-line consolidation strategy for LBCL, presenting significant regulatory, commercial, and operational risks.
• The company may encounter substantial delays in clinical trials or may not be able to conduct trials on expected timelines due to various factors including patient enrollment, regulatory consensus, or manufacturing issues.
• Difficulties enrolling patients in clinical trials, particularly for ALPHA3 due to high screen failure rates for MRD+ patients, could delay or adversely affect clinical development.
• Failure to successfully manufacture product candidates, operate the manufacturing facility (CF1), or obtain regulatory approval for its use could adversely affect clinical trials and commercial viability.
• Reduced manufacturing operations following the May 2025 workforce reduction may limit the ability to timely support development programs and maintain operational readiness.
• Significant competition from other biotechnology and pharmaceutical companies could impact market share and pricing.
• High dependence on key personnel; inability to attract and retain highly qualified personnel could hinder business strategy implementation.
• Disruptions to the operations of the FDA, SEC, and other government agencies (e.g., funding shortages, staffing cuts) could delay regulatory review and approval processes.
• Uncertainty exists regarding whether the use of fludarabine and cyclophosphamide (FC) without ALLO-647 will achieve sufficient lymphodepletion to support the efficacy of allogeneic CAR T in the ALPHA3 trial.
• Heavy reliance on partners Cellectis and Servier for access to TALEN gene editing technology; potential for disputes or termination of licenses.
• Heavy reliance on Foresight Diagnostics for access to their CLARITY MRD test for ALPHA3 patient identification, with risks related to performance, regulatory approval, and timely execution.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Stringent and evolving U.S. and foreign laws, regulations, and industry standards related to data privacy and security could lead to enforcement actions, litigation, or business disruptions.
• Unstable market, economic, and geopolitical conditions (e.g., tariffs, wars, bank failures) may have serious adverse consequences on business, financial condition, and stock price.
• Sales of a substantial number of shares by existing stockholders could cause the stock price to fall.
• Failure to establish and maintain effective internal control over financial reporting could result in material misstatements and loss of investor confidence.

Future Outlook

The company expects to continue incurring net losses for the foreseeable future, with research and development and general and administrative expenses anticipated to increase. Current cash, cash equivalents, and investments are projected to fund operations into the second half of 2027. The next key milestone for the ALPHA3 trial is a futility analysis comparing minimal residual disease (MRD) conversion rates, expected in the first half of 2026. The company is actively exploring strategic opportunities, including potential partnerships, to advance the ALLO-316 program. Guidance on additional milestones beyond the ALPHA3 futility analysis will be provided after that milestone.

Management Comments

• We believe we currently hold sufficient inventory of cema-cel, ALLO-329, and ALLO-316 to meet our near-term clinical needs, including completing our current ALPHA3, RESOLUTION and TRAVERSE trials.
• We expect that our cash, cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).
• We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses and general and administrative expenses will continue to increase.
• We continue to actively explore strategic opportunities, including potential partnerships, to advance this program [ALLO-316].
• We anticipate having proof-of-concept data by the first half of 2026, which we anticipate will include both biomarker and clinical data [for ALLO-329].
• We expect to provide the rates of MRD conversion between the two arms at the time of this announcement [ALPHA3 futility analysis].
• As we seek to better understand the effectiveness of our updated enrollment strategies, we are currently not providing guidance regarding the timing of additional milestones beyond the futility analysis, but expect to do so following such milestone.

Industry Context

Allogene Therapeutics operates in the highly competitive and rapidly evolving immuno-oncology and cell therapy sectors, specifically pioneering allogeneic (off-the-shelf) CAR T cell therapies. This approach aims to overcome the logistical and cost challenges of autologous therapies by providing readily available treatments. The industry is characterized by intense competition from major pharmaceutical and biotechnology companies, as well as rapid innovation in gene-editing technologies and new therapeutic modalities like bispecific antibodies. The regulatory landscape for novel cell and gene therapies is still developing, leading to uncertainties in approval pathways and potential for evolving safety requirements, as evidenced by the FDA's recent black box warning for T-cell malignancies in autologous CAR T therapies. The company's reliance on novel diagnostic assays and complex manufacturing processes places it at the forefront of innovation but also exposes it to unique technical and regulatory risks.

Comparison to Industry Standards

• Allogene's allogeneic (off-the-shelf) CAR T cell approach aims to offer advantages in speed, reliability, and scale compared to autologous CAR T therapies (e.g., Novartis' Kymriah, Gilead's Yescarta), which are patient-specific and involve longer manufacturing times.
• The Grade 5 serious adverse event in the ALPHA3 trial's FCA arm, attributed to ALLO-647, highlights a specific safety challenge related to lymphodepletion regimens in allogeneic CAR T, which may differ from the adverse event profiles observed in autologous CAR T trials.
• The FDA's recent requirement for a black box warning on BCMAand CD19-directed autologous T-cell immunotherapies (e.g., Abecma, Carvykti, Yescarta, Kymriah, Breyanzi) for T-cell malignancies indicates a broader safety concern within the CAR T field, which Allogene's similar technology may also encounter as more patients are treated.
• The company's strategy to target first-line consolidation in LBCL with cema-cel, utilizing a novel MRD assay (Foresight Diagnostics PhasED-Seq), represents a distinct clinical development path compared to existing CAR T approvals primarily in relapsed/refractory settings.
• Allogene's pursuit of autoimmune disease indications with ALLO-329 (e.g., SLE, IIM, SSc) positions it in an emerging area for CAR T therapy, distinct from the established oncology focus of many competitors.

Management Changes

Legal Proceedings

• Roche Molecular Systems, Inc. and Roche Sequencing Solutions, Inc. filed lawsuits against Foresight Diagnostics Inc., Stanford University, and three of Foresight's founders, alleging misappropriation of trade secrets, unfair competition, and breach of contract relating to Foresight Diagnostics' PhasED-Seq Circulating Tumor DNA Platform. A term sheet to resolve the litigation for all parties has been entered, with a definitive settlement agreement expected by August 29, 2025.
• Cellectis S.A. initiated an arbitration proceeding against Servier, seeking a decision terminating the Servier-Cellectis Agreement and seeking certain compensation. The arbitral decision is expected to be rendered on or before December 15, 2025.

Related Party Transactions

• Sublease agreement with Bellco Capital LLC (controlled by Executive Chairman Arie Belldegrun, M.D.) for 2,218 square feet of office space in Los Angeles, California. The sublease commenced on January 1, 2024, with a total right-of-use asset of $2.1 million and associated lease liability of $2.4 million as of June 30, 2025. Rent expense was $0.1 million for Q2 2025 and $0.2 million for H1 2025.
• Consulting agreement with Bellco (controlled by Executive Chairman Arie Belldegrun, M.D.) for services provided by Dr. Belldegrun. Costs incurred were $0.2 million for Q2 2025 and $0.4 million for H1 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity capital raises and continued stock price volatility influenced by clinical trial outcomes, regulatory decisions, and ongoing legal disputes involving partners.
• Employees experienced a significant workforce reduction of approximately 28% in May 2025, leading to job losses and potential impacts on morale and retention for the remaining staff.
• Patients may benefit from the advancement of novel allogeneic CAR T therapies, but face risks of serious adverse events in clinical trials (e.g., the Grade 5 SAE in ALPHA3) and potential delays in access to investigational treatments.
• Creditors and suppliers are exposed to the company's continued operating losses and reliance on future capital raises, although the extended cash runway provides some near-term financial stability.

Next Steps

• Conduct futility analysis comparing minimal residual disease (MRD) conversion rates in the ALPHA3 trial, expected in the first half of 2026.
• Provide rates of MRD conversion between the two arms of the ALPHA3 trial at the time of the futility analysis announcement.
• Seek scientific advice from EU and UK regulatory authorities to finalize the regulatory strategy for cema-cel in those regions.
• Actively explore strategic opportunities, including potential partnerships, to advance the ALLO-316 development program.
• Continue to assess the impact of ASU 2024-03 on the consolidated financial statements and disclosures.
• Negotiate and finalize a definitive settlement agreement between Roche and Foresight Diagnostics by August 29, 2025, to resolve the litigation.
• Await the arbitral decision in the Cellectis vs. Servier dispute, expected on or before December 15, 2025.

Key Dates

Recommendation

While Allogene Therapeutics has extended its cash runway and is making progress in its clinical pipeline with RMAT and Fast Track designations, the company continues to incur substantial net losses and has a significant accumulated deficit. The recent Grade 5 serious adverse event in the ALPHA3 trial, leading to the discontinuation of ALLO-647, introduces clinical uncertainty and highlights the inherent risks of novel cell therapies. The ongoing legal disputes involving key partners (Servier/Cellectis, Foresight/Roche) add further complexity. Given the high-risk nature of clinical-stage biotech, the need for future capital raises, and the mixed clinical and financial signals, a 'Hold' recommendation is appropriate for investors who are already exposed to the stock and are willing to monitor the upcoming clinical milestones and resolution of legal matters. New investors should exercise caution due to the significant risks.

Keywords

Allogene Therapeutics, Immuno-oncology, CAR T cell therapy, Allogeneic, Cancer treatment, Autoimmune diseases, Clinical trials, ALPHA3, TRAVERSE, RESOLUTION, LBCL, RCC, SLE, IIM, SSc, Gene editing, TALEN, CD19, CD70, BCMA, Dagger Platform, SEC filing, Biotechnology, Pharmaceutical, Clinical stage, Cell therapy, Workforce reduction, Cash runway